{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:19:22Z","timestamp":1793643562224,"version":"4.5.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000777","name":"University of Leeds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000777","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011703","name":"Yorkshire Cancer Research","doi-asserted-by":"publisher","award":["L374RA"],"award-info":[{"award-number":["L374RA"]}],"id":[{"id":"10.13039\/100011703","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000402","name":"Kay Kendall Leukaemia Fund","doi-asserted-by":"publisher","award":["KKL1071"],"award-info":[{"award-number":["KKL1071"]}],"id":[{"id":"10.13039\/501100000402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000739","name":"University of Southampton","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009033","name":"NHS Blood and Transplant","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.omto.2023.03.002","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T22:15:21Z","timestamp":1679609721000},"page":"17-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells"],"prefix":"10.1016","volume":"29","author":[{"given":"Matthew","family":"Holmes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina B.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Heaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basem","family":"Askar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise M.E.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria A.","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Ralph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Melcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hillmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Parrish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2155-534X","authenticated-orcid":false,"given":"Fiona","family":"Errington-Mais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2023.03.002_bib1","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/nri953","article-title":"Lymphoid malignancies: the dark side of B-cell differentiation","volume":"2","author":"Shaffer","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omto.2023.03.002_bib2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omto.2023.03.002_bib3","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/10428194.2016.1204654","article-title":"Modeling the chronic lymphocytic leukemia microenvironment in\u00a0vitro","volume":"58","author":"Crassini","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.omto.2023.03.002_bib4","doi-asserted-by":"crossref","first-page":"8750","DOI":"10.18632\/oncotarget.3275","article-title":"Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma","volume":"6","author":"Chiron","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.omto.2023.03.002_bib5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41419-017-0157-6","article-title":"CD40L mediated alternative NFkappaB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma","volume":"9","author":"Rauert-Wunderlich","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omto.2023.03.002_bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1471-2407-6-75","article-title":"CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways","volume":"6","author":"Voorzanger-Rousselot","year":"2006","journal-title":"BMC cancer"},{"key":"10.1016\/j.omto.2023.03.002_bib7","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.ccell.2016.11.002","article-title":"Characterization of rare, dormant, and therapy-resistant cells in acute lymphoblastic leukemia","volume":"30","author":"Ebinger","year":"2016","journal-title":"Cancer cell"},{"key":"10.1016\/j.omto.2023.03.002_bib8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrc.2017.125","article-title":"Targeting minimal residual disease: a path to cure?","volume":"18","author":"Luskin","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omto.2023.03.002_bib9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic viruses and the immune system: the dynamic duo. Molecular therapy","volume":"17","author":"Lemos de Matos","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omto.2023.03.002_bib10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s40425-019-0632-y","article-title":"Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21","volume":"7","author":"M\u00fcller","year":"2019","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omto.2023.03.002_bib11","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1503032","article-title":"Trial Watch: oncolytic viro-immunotherapy of hematologic and solid tumors","volume":"7","author":"Pol","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.omto.2023.03.002_bib12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4137\/BIC.S33378","article-title":"Oncogenes: the passport for viral oncolysis through PKR inhibition","volume":"8","author":"Fernandes","year":"2016","journal-title":"Biomark. Cancer"},{"key":"10.1016\/j.omto.2023.03.002_bib13","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.trecan.2015.10.004","article-title":"Oncolytic viruses: exploiting cancer's deal with the devil","volume":"1","author":"Pikor","year":"2015","journal-title":"Trends Cancer"},{"key":"10.1016\/j.omto.2023.03.002_bib14","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1158\/1078-0432.CCR-11-2181","article-title":"Phase I\/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies","volume":"18","author":"Karapanagiotou","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2023.03.002_bib15","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1158\/1078-0432.CCR-10-0054","article-title":"Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers","volume":"16","author":"Harrington","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2023.03.002_bib16","doi-asserted-by":"crossref","first-page":"5946","DOI":"10.1158\/1078-0432.CCR-14-1404","article-title":"A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma","volume":"20","author":"Sborov","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2023.03.002_bib17","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2023.03.002_bib18","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.mayocp.2014.04.003","article-title":"Remission of disseminated cancer after systemic oncolytic virotherapy","volume":"89","author":"Russell","year":"2014","journal-title":"Mayo Clin. Proc."},{"issue":"Suppl","key":"10.1016\/j.omto.2023.03.002_bib19","article-title":"Broad targeting of resistance to apoptosis in cancer","volume":"35 Suppl","author":"Mohammad","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.omto.2023.03.002_bib20","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/gt.2008.58","article-title":"Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma","volume":"15","author":"Errington","year":"2008","journal-title":"Gene Ther."},{"key":"10.1016\/j.omto.2023.03.002_bib21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/cgt.2015.30","article-title":"Dual silencing of Bcl-2 and Survivin by HSV-1 vector shows better antitumor efficacy in higher PKR phosphorylation tumor cells in\u00a0vitro and in\u00a0vivo","volume":"22","author":"Chen","year":"2015","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omto.2023.03.002_bib22","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1158\/1078-0432.CCR-1083-3","article-title":"Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells","volume":"10","author":"Stanziale","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2023.03.002_bib23","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1099\/jgv.0.000980","article-title":"Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update","volume":"98","author":"Felt","year":"2017","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.omto.2023.03.002_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/OV.S56322","article-title":"Applications of coxsackievirus A21 in oncology","volume":"3","author":"Bradley","year":"2014","journal-title":"Oncolytic Virother."},{"key":"10.1016\/j.omto.2023.03.002_bib25","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1158\/1078-0432.CCR-18-4022","article-title":"Phase I trial of an ICAM-1-targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer","volume":"25","author":"Annels","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2023.03.002_bib26","doi-asserted-by":"crossref","first-page":"P343","DOI":"10.1186\/2051-1426-3-S2-P343","article-title":"Phase II calm extension study: coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment","volume":"3","author":"Andtbacka","year":"2015","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omto.2023.03.002_bib27","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/1743-422X-8-473","article-title":"Cytolytic replication of echoviruses in colon cancer cell lines","volume":"8","author":"Israelsson","year":"2011","journal-title":"Virol. J."},{"key":"10.1016\/j.omto.2023.03.002_bib28","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","article-title":"Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma","volume":"27","author":"Senzer","year":"2009","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2023.03.002_bib29","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1128\/jvi.71.6.4736-4743.1997","article-title":"Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry","volume":"71","author":"Shafren","year":"1997","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2023.03.002_bib30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/CJI.0b013e31814a69fa","article-title":"Cross-linking of CD54 on Burkitt lymphoma cell line Raji and Ramos induces FasL expression by reactive oxygen species and apoptosis of adjacent cells in Fas\/FasL interaction","volume":"30","author":"Kim","year":"2007","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omto.2023.03.002_bib31","first-page":"3195","article-title":"In\u00a0vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma","volume":"62","author":"Briones","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2023.03.002_bib32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.cr.7290165","article-title":"Coxsackievirus B3-induced apoptosis and caspase-3","volume":"13","author":"Yuan","year":"2003","journal-title":"Cell Res."},{"key":"10.1016\/j.omto.2023.03.002_bib33","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.bbrc.2013.10.142","article-title":"Coxsackievirus A16 infection triggers apoptosis in RD cells by inducing ER stress","volume":"441","author":"Zhu","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omto.2023.03.002_bib34","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1111\/j.1462-5822.2007.00964.x","article-title":"Coxsackievirus B3 activates nuclear factor kappa B transcription factor via a phosphatidylinositol-3 kinase\/protein kinase B-dependent pathway to improve host cell viability","volume":"9","author":"Esfandiarei","year":"2007","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.omto.2023.03.002_bib35","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1128\/JVI.78.8.4289-4298.2004","article-title":"Protein kinase B\/Akt regulates coxsackievirus B3 replication through a mechanism which is not caspase dependent","volume":"78","author":"Esfandiarei","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2023.03.002_bib36","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/annonc\/mdt530","article-title":"The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases","volume":"25","author":"Hong","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omto.2023.03.002_bib37","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/484537","article-title":"Constitutive NF- kappa B activation underlines major mechanism of drug resistance in relapsed refractory diffuse large B cell lymphoma","volume":"2015","author":"Turturro","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.omto.2023.03.002_bib38","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/cei.12562","article-title":"Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in\u00a0vivo","volume":"180","author":"El-Sherbiny","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.omto.2023.03.002_bib39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1677\/erc.0.0060021","article-title":"Survival signals within the tumour microenvironment suppress drug-induced apoptosis: lessons learned from B lymphomas","volume":"6","author":"Taylor","year":"1999","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.omto.2023.03.002_bib40","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/s41418-020-00692-w","article-title":"Regulation of Bcl-XL by non-canonical NF-\u03baB in the context of CD40-induced drug resistance in CLL","volume":"28","author":"Haselager","year":"2021","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.omto.2023.03.002_bib41","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1200\/JCO.20.03246","article-title":"Clinical responses of oncolytic coxsackievirus A21 (V937) in patients with unresectable melanoma","volume":"39","author":"Andtbacka","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2023.03.002_bib42","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/leu.2015.88","article-title":"Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia","volume":"29","author":"Parrish","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.omto.2023.03.002_bib43","volume":"7","author":"Dogliotti","year":"2018"},{"key":"10.1016\/j.omto.2023.03.002_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omto.2018.02.001","article-title":"Oncolytic immunotherapy for bladder cancer using coxsackie A21 virus","volume":"9","author":"Annels","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omto.2023.03.002_bib45","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.omto.2023.03.002_bib46","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1512455","article-title":"Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model","volume":"8","author":"Chu","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.omto.2023.03.002_bib47","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.semcancer.2013.09.001","article-title":"B-cell receptor signaling as a driver of lymphoma development and evolution","volume":"23","author":"Niemann","year":"2013","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.omto.2023.03.002_bib48","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11010-013-1825-1","article-title":"LY294002 and Rapamycin promote coxsackievirus-induced cytopathic effect and apoptosis via inhibition of PI3K\/AKT\/mTOR signaling pathway","volume":"385","author":"Chen","year":"2014","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.omto.2023.03.002_bib49","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nm.3848","article-title":"Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity","volume":"21","author":"Ilkow","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2023.03.002_bib50","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3109\/10428194.2011.654337","article-title":"CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in\u00a0vitro preclinical studies with primary B-cell malignancies","volume":"53","author":"Ito","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.omto.2023.03.002_bib51","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omto.2023.03.002_bib52","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41592-018-0071-6","article-title":"A human immune system mouse model with robust lymph node development","volume":"15","author":"Li","year":"2018","journal-title":"Nat. Methods"},{"key":"10.1016\/j.omto.2023.03.002_bib53","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.1073\/pnas.1220456110","article-title":"Interferon-\u03b3 mediates chemokine-dependent recruitment of natural killer cells during viral infection","volume":"110","author":"Pak-Wittel","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omto.2023.03.002_bib54","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/gt.2009.29","article-title":"Dendritic cells and T\u00a0cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity","volume":"16","author":"Ilett","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.omto.2023.03.002_bib55","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1073\/pnas.91.9.3515","article-title":"Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T\u00a0cells infiltrating into tumor","volume":"91","author":"Kawakami","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omto.2023.03.002_bib56","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1158\/1078-0432.CCR-07-5158","article-title":"DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia","volume":"14","author":"Willmore","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2023.03.002_bib57","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.ymthe.2019.04.008","article-title":"Potentiating oncolytic virus-induced immune-mediated tumor cell killing using histone deacetylase inhibition","volume":"27","author":"Jennings","year":"2019","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770523000244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770523000244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:24:25Z","timestamp":1762496665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770523000244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":57,"alternative-id":["S2372770523000244"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2023.03.002","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2023.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}]}}